AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|
31.2 C
New York
Wednesday, July 1, 2026

Tag: patient

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

OneOncology and Pacific Cancer Care Expand Central Coast Cancer Services with Acquisition of Los Gatos Radiation Oncology Center

NASHVILLE, Tenn. and MONTEREY, Calif., July 1, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform supporting independent oncology practices, and its Monterey-based partner Pacific Cancer...

Relm Appoints Dr Rayyan Zafar As Senior Scientific Advisor As Part Of Strategic Expansion In Alternative Therapeutics Sector

Bermuda, July 01, 2025 (GLOBE NEWSWIRE) -- - Relm Insurance (‘Relm’), the leading insurer for emerging and innovative industries, today announced the appointment of Dr. Rayyan Zafar, PhD, MRSB, as a Senior Scientific Advisor to the firm. In this role, Dr. Zafar will inform Relm’s strategic expansion into the emerging field of Psychedelics and Alternative Therapeutics, leveraging his world-class expertise to deepen Relm’s understanding of novel treatments for addiction and mental health disorders.

CMI Media Group Announces 2025 Agility Berlin Event; Martin Strobel to Keynote

Strategic media healthcare agency CMI Media Group, a WPP company, announces the inaugural event, Agility Berlin, 16 October at The Spielfeld.

TeleVox Launches Innovative Planned Outreach Program, Expanding Access to Proactive Patient Care for Small Practices

OMAHA, Neb., July 01, 2025 (GLOBE NEWSWIRE) -- TeleVox, the industry-leading provider of omnichannel patient relationship management platforms, is addressing the outreach gap in patient care with the launch of the Planned Outreach Program. This new solution, integrated within the award-winning TeleVox Practice Edition platform, is designed to drive patient engagement results for small practices with smart, automated outreach.

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

Dr. Michael Lebow Launches Nationwide Scholarship Initiative to Support Aspiring Healthcare Professionals in the United States

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- The Dr. Michael Lebow Scholarship for Future Doctors is now officially open for applications, inviting undergraduate students across the United States to compete for a one-time academic award designed to support and encourage future leaders in the healthcare field. This prestigious scholarship, created by esteemed vascular surgeon Dr. Michael Lebow, is committed to recognizing students who have demonstrated academic excellence, a passion for medicine, and a clear vision for positively impacting the healthcare industry.

TRC Healthcare Launches Upgraded NatMed Pro to Further Support Evidence-Based Natural Medicine Use with Smarter Tools

DENVER, July 1, 2025 /PRNewswire/ -- TRC Healthcare, the leading provider of evidence-based medication-related resources, announced last week the launch of an upgraded NatMed...

atai Life Sciences Announces $50 Million Private Placement Financing

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss

Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist
Rincell-1 addresses a multi $Bn global market opportunity  where no disease modifying treatments currently exist

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient